

# Global Oral Mucositis Drugs and Companies Pipeline Review H2 2016

*Oral Mucositis Therapeutic Pipeline Market Review, H2 2016*

PUNE, INDIA, September 19, 2016  
/EINPresswire.com/ -- [Oral Mucositis](#) - Pipeline Review, H2 2016

## Summary

'Oral Mucositis - Pipeline Review, H2 2016', provides an overview of the Oral Mucositis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects.



Complete report details @ <https://www.wiseguyreports.com/reports/643483-oral-mucositis-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/643483-oral-mucositis-pipeline-review-h2-2016>

Scope

- The report provides a snapshot of the global therapeutic landscape of Oral Mucositis
- The report reviews pipeline therapeutics for Oral Mucositis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Oral Mucositis therapeutics and enlists all their major and minor projects
- The report assesses Oral Mucositis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Oral Mucositis

#### Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Oral Mucositis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/643483-oral-mucositis-pipeline-review-h2-2016>

#### Key Points in Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Oral Mucositis Overview 8

Therapeutics Development 9

Pipeline Products for Oral Mucositis - Overview 9

Pipeline Products for Oral Mucositis - Comparative Analysis 10

Oral Mucositis - Therapeutics under Development by Companies 11

Oral Mucositis - Therapeutics under Investigation by Universities/Institutes 12

Oral Mucositis - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Oral Mucositis - Products under Development by Companies 16

Oral Mucositis - Products under Investigation by Universities/Institutes 17

Oral Mucositis - Companies Involved in Therapeutics Development 18

Aldeyra Therapeutics, Inc. 18

Cellceutix Corporation 19

Colby Pharmaceutical Company 20

Daewoong Pharmaceutical Co., Ltd. 21

Galera Therapeutics, Inc. 22

Onxeo SA 23

Oragenics, Inc. 24

Otsuka Holdings Co., Ltd. 25

Soligenix, Inc. 26

Spectrum Pharmaceuticals, Inc. 27

Spherium Biomed S.L. 28

Oral Mucositis - Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

AG-013 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

brilacidin tetrahydrochloride - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

clonidine hydrochloride ER - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

dusquetide - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

GC-4419 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Gene Therapy for Oral Mucositis - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Gene Therapy for Oral Mucositis - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

KIN-219 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

nepidermin - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

NS-2 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

pralatrexate - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

rebamipide - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Recombinant Protein for Immunology, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

SP-13004 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Buy this report @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=643483](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=643483)

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.